Adalimumab versus placebo as add-on to standard therapy for non-infectious uveitis in the United Kingdom: the ASTUTE randomised controlled trial with treatment run-in
Adalimumab versus placebo as add-on to standard therapy for non-infectious uveitis in the United Kingdom: the ASTUTE randomised controlled trial with treatment run-in. // eClinicalMedicine. – URL: https://www.sciencedirect.com/science/article/pii/S2589537026004931?dgcid=rss_sd_all
Adalimumab versus placebo as add-on to standard therapy for non-infectious uveitis in the United Kingdom: the ASTUTE randomised controlled trial with treatment run-in. eClinicalMedicine. https://www.sciencedirect.com/science/article/pii/S2589537026004931?dgcid=rss_sd_all
“Adalimumab versus placebo as add-on to standard therapy for non-infectious uveitis in the United Kingdom: the ASTUTE randomised controlled trial with treatment run-in.” eClinicalMedicine.
@article{article100080,
title = {Adalimumab versus placebo as add-on to standard therapy for non-infectious uveitis in the United Kingdom: the ASTUTE randomised controlled trial with treatment run-in},
journal = {eClinicalMedicine},
url = {https://www.sciencedirect.com/science/article/pii/S2589537026004931?dgcid=rss_sd_all}
}
ABSTRACT As leadership education continues to evolve, increasing attention has been given to fostering learners’ leadership identity, capacity, and efficacy. Drawing on collaborative conversations with 12 leadership educators...